comparemela.com

Latest Breaking News On - Immunology for the international developed - Page 1 : comparemela.com

Hansa Biopharma interim report January-March 2023

/PRNewswire/ Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and.

United kingdomUnited statesDonato spotaHansa biopharmaMedison pharmaMatthew shaulisStephanie kenneyPrnewswire hansa biopharmaKlaus sindahlImmunology for the international developedVp global corporate affairsChief commercial officerInternational developed marketsNorth america oncologySenior vice presidentHalf year report

Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma

/PRNewswire/ Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that.

United statesHansa biopharmaPrnewswire hansa biopharmaStephanie kenneyKlaus sindahlMatthew shaulisHenk doude van troostwijkImmunology for the international developedHansa biopharma incVp global corporate affairsChief commercial officerHenk doudeVice presidentCommercial excellenceInternational developed marketsNorth america oncology

vimarsana © 2020. All Rights Reserved.